Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 77.54% from the stock’s current price. A number […]

Related Keywords

Switzerland , Swiss , , Praxis Precision Medicines Company Profile , York Mellon Corp , Metlife Investment Management , Jpmorgan Chase Co , Praxis Precision Medicines Inc , Swiss National Bank , Praxis Precision Medicines , Get Free Report , Precision Medicines , National Bank , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , Praxis Precision Medicines Daily , Nasdaq Prax , Aprax , Medical , Reiterated Rating , Hc Wainwright ,